State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent

Area of Science:

• Herbal medicine
• Oncology
• Natural compounds

Background:

• Cancer is a leading global cause of death.
• Current cancer treatments have significant side effects and drug resistance issues.
• Natural compounds and herbal medicines are being explored as alternative chemopreventive agents.

Purpose of the Study:

• To review and present findings on the anticancer potential of SH003.
• To summarize research on SH003, a herbal medicine composed of Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii.
• To assess the current evidence for SH003's efficacy and safety in cancer treatment.

Main Methods:

• A narrative review of 15 studies on SH003 conducted over the past nine years.
• Analysis of in vitro and in vivo studies investigating SH003's effects on cancer cells.
• Review of the first clinical trial assessing the maximum tolerated dose of SH003 in solid cancer patients.

Main Results:

• SH003 demonstrated positive anticancer effects in both in vitro and in vivo experimental models.
• Studies indicate SH003's potential efficacy against various cancer cell types.
• The initial clinical trial established the maximum tolerated dose for SH003 in patients with solid tumors.

Conclusions:

• SH003 exhibits potential as a chemotherapeutic agent with documented anticancer properties.
• Continued research into SH003's efficacy and safety is essential for its clinical application.
• Further investigation is required to determine SH003's viability as a pharmaceutical cancer treatment.